Original researchOutcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment
Cited by (0)
Contributors: AB collected and analysed data, contributed to interpretation of data and drafted the manuscript, figures and tables. AD collected data and reviewed the final manuscript. AC contributed to data analysis. EN contributed to data collection. JA, ER, MK and VH contributed to data collection and interpretation of data. SD, MB, MF, CH, PM and ALC reviewed the manuscript. J-YB contributed to interpretation of data and reviewed the manuscript. OM designed the study, collected data, analysed data and reviewed the manuscript. All authors approved the final version of the manuscript.
Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests: JA has a consulting or advisory role for AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme and Roche; and research funding from Merck Sharp & Dohme (Inst) and Pierre Fabre (Inst). ER received honoraria from AstraZeneca (Inst), BMS (Inst) and Roche (Inst), has a consulting or advisory role for AstraZeneca, research funding from AstraZeneca (Inst) and accommodation expenses from AstraZeneca and BMS. MF received honoraria from Novartis (Inst) and accommodation expenses from Ipsen, Novartis and Pfizer. ALC received honoraria from Bayer, Lilly and PharmaMar. J-YB has leadership of Innate Pharma; received honoraria from AstraZeneca, BMS, MSD, PharmaMar and Roche; has a consulting or advisory role for Bayer, Blueprint, Deciphera, Pharmamar and Roche; received research funding from Bayer (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Pharmamar (Inst) and Roche (Inst); and received accommodation expenses from Roche. OM has stock and other ownership interests in Amplitude Surgical, Ipsen and Transgene; honoraria from Roche; a consulting or advisory role for Janssen, Lilly, Lundbeck, Pfizer and Roche; is in the speakers’ bureau of Lilly, Pfizer and Roche; and received accommodation expenses from Pfizer and Roche. Other authors have no conflicts of interest to declare.
Patient consent for publication: Not required.
Ethics approval: Study was approved by Gustave Rousy IRB (Registration Number: 2020-45).
Provenance and peer review: Not commissioned; externally peer reviewed.
Data availability statement: Data are available upon reasonable request.